Europe Secures Insulin Supply: New Production Facility Planned in Frankfurt-Höchst
The federal government, the state of Hesse, and the city of Frankfurt are jointly supporting the project
Advertisement
The European Commission has approved funding for the construction and modernization of Sanofi’s insulin production facility in Frankfurt-Höchst. The state of Hesse welcomes the EU’s decision. Sanofi is investing in a new, state-of-the-art insulin production facility at the site. The public funding is intended to ensure a sufficient and resilient supply of insulin in Germany and Europe in the long term. To this end, as part of a service of general economic interest (SGEI), Sanofi is assuming specific obligations to maintain production and stockpiling capacities and to ensure supply, particularly during crises and supply shortages.
“From the very beginning, we have been strongly committed to ensuring that Sanofi secures insulin production in Frankfurt-Höchst for the long term. The European Commission’s decision brings us a decisive step closer to this goal. In doing so, we are maintaining a strategically important value chain in Hesse, strengthening supply security in Germany and Europe, and providing highly qualified employees at the site with long-term prospects. At the same time, this investment demonstrates that active industrial policy can make a difference when the state, federal government, and local authorities work together to support a location,” said Kaweh Mansoori, Hesse’s Minister of Economic Affairs and Deputy Minister-President.
The insulin market is highly concentrated. At the same time, there are only a few production sites in Europe where the active ingredient is also manufactured. A loss of production in Frankfurt-Höchst would significantly increase dependence on imports. The funding is therefore tied to specific commitments: Sanofi will build a new insulin production facility at the site and, for the duration of the mandate, will assume specific obligations to provide production capacity, maintain stockpiles, and ensure the supply of insulin in Germany and Europe—particularly during supply shortages or crisis situations.
Working Together for a Strong Pharmaceutical and Industrial Hub
Funding for the project is provided jointly by the federal government, the state of Hesse, and the city of Frankfurt. With approval from the European Commission, a key prerequisite for the granting of funding has been met.
For Hesse, the investment holds great significance for industrial policy beyond simply securing the insulin supply. Frankfurt-Höchst is one of the state’s most important pharmaceutical and chemical hubs. The investment preserves industrial production expertise and value creation at the site and strengthens its competitive position on the international stage.
Sanofi has decided to build the new insulin production facility in Germany at the Frankfurt-Höchst site and has ruled out relocating production abroad. The new facility will modernize insulin production at the site and secure it for the long term.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
